Roche
NICE turns down Roche’s Perjeta for post-surgery HER2-positive breast cancer
June 15, 2018Medical Communications, Sales and Marketing Cancer, NICE, Perjeta, Roche, breast cancer, pharma
Roche’s ongoing dispute with UK health service watchdog NICE over the availability of its monoclonal antibody Perjeta (pertuzumab) on the …
Roche’s Ocrevus extends time-to-wheelchair by 7 years in progressive MS patients
June 14, 2018Research and Development Ocrevus, Roche, multiple sclerosis, pharma
Roche has lifted the curtain on more promising data at Phase 3 for its humanised anti-CD20 monoclonal antibody Ocrevus (ocrelizumab), …
AbbVie/Roche gain FDA approval for blockbuster treatment
June 11, 2018Sales and Marketing AbbVie, Roche, biotech, drugs, pharma, pharmaceutical
AbbVie and Roche have a chalked up a major success, after the FDA gave its approval for Venclexta, in combination …
Roche’s breast, lung cancer offerings fail to impress at ASCO
June 4, 2018Research and Development, Sales and Marketing ASCO, Cancer, Roche, breast cancer, lung cancer, pharma, taselisib, tecentriq
Roche made an underwhelming impact at the American Society of Clinical Oncology (ASCO) annual event in Chicago, after revealing data …
Roche resigns itself to failure on SMA drug
June 1, 2018Medical Communications Roche, biotech, drugs, pharma, pharmaceutical, spinal muscular atrophy
Roche has announced that it will no longer seek to develop its treatment for spinal muscular atrophy (SMA), olesoxime, after …
Roche’s Tecentriq/chemo combo smashes both co-primary endpoints at Phase 3
May 29, 2018Manufacturing and Production, Research and Development Cancer, NSCLC, Roche, immunotherapy, lung cancer, pharma, tecentriq
Roche has lifted the curtain on new Phase 3 data for its anti-PD-L1 cancer immunotherapy Tecentriq (atezolizumab), showing that the …
J&J terminates PD-(L)1 combo studies of cancer therapy Darzalex
May 29, 2018Manufacturing and Production, Research and Development Cancer, Genmab, J&J, JJ, Johnson & Johnson, Roche, darzalex, multiple myeloma, tecentriq
Johnson & Johnson is to terminate its studies investigating Genmab’s CD38-targeting, human IgG1κ monoclonal antibody Darzalex (daratumumab) in combination with …
Prothena guts workforce by more than half, after trial failure
May 25, 2018Medical Communications Neil Woodford, Prothena, Roche, biotech, drugs, pharma, pharmaceutical
Prothena Therapeutics has acted drastically by slashing staff numbers by more than half, after the failure of two pivotal trials …
Roche’s Hemlibra stakes claim to be haemophilia market leader
May 21, 2018Research and Development, Sales and Marketing Hemlibra, Roche, Shire, biotech, drugs, haemophilia, pharma, pharmaceutical
Hemlibra was widely expected to become the dominant therapeutic for treating haemophilia patients and its latest clinical trial results only …
Study finds Herceptin use can be halved
May 17, 2018Medical Communications, Research and Development Herceptin, Roche, biosimilars, biotech, drugs, pharma, pharmaceutical
A team of researchers from the University of Cambridge and Warwick Clinical Trials have revealed that Roche’s Herceptin is just …
Roche gets NICE approval for advanced bladder cancer
May 17, 2018Sales and Marketing Roche, biotech, drugs, pharma, pharmaceutical, tecentriq
Though trial results for Tecentriq (atezolizumab) may not necessarily be going Roche’s way, after a combination treatment failure, the treatment …
Roche’s Tecentriq/Cotellic combo therapy fails to impress in colorectal cancer
May 11, 2018Medical Communications, Research and Development Cancer, Cotellic, Roche, pharma, tecentriq
Roche has been rocked by a Phase 3 weak showing from its combination Tecentriq (atezolizumab) and Cotellic (cobimetinib) in people …
Lodo and Roche go digging for drug candidates, after $1bn deal
May 10, 2018Sales and Marketing Genentech, Roche, biotech, drugs, pharma, pharmaceutical
Discovering potential therapeutics from natural sources has been a constant throughout the evolution of medicine, Lodo Therapeutics, however, has taken …
Top Ten most popular articles on Pharmafile.com this week
May 4, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing BMS, EMA, Kymriah, Novartis, Porton Biopharma, Regeneron, Roche, Sandoz, Sanofi, Shire, Takeda, biosimilars, dementia
It’s Friday again and it’s been a week busy with companies’ financials. One company’s in particular were of note due …
EMA’s CHMP backs Roche’s Perjeta combo in HER2-positive breast cancer
April 30, 2018Sales and Marketing Cancer, Herceptin, Perjeta, Roche, breast cancer, pharma
Roche’s Perjeta has edged one step closer to approval as a combo therapy after the EMA’s Committee for Medicinal Products …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
